PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31287994-2	2019	Mubritinib, a known ERBB2 inhibitor, elicited strong anti-leukemic effects in vitro and in vivo.	TAK-165	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	20-25	
33245718-9	2020	Mubritinib was originally identified as a receptor tyrosine kinase (RTK) inhibitor selective for HER2/ErbB2.	TAK-165	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	97-101	
33245718-9	2020	Mubritinib was originally identified as a receptor tyrosine kinase (RTK) inhibitor selective for HER2/ErbB2.	TAK-165	0-10	erb-b2 receptor tyrosine kinase 2	Homo sapiens	102-107	
27074819-0	2016	The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARalpha/STAT1 axis.	TAK-165	19-25	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-8	
29374185-6	2018	We identified that TAK-165, a HER2 inhibitor, even when used at low nanomolar doses in combination with AC220, was able to induce cell death in different cancer cells, but not in non-cancer cell lines.	TAK-165	19-26	erb-b2 receptor tyrosine kinase 2	Homo sapiens	30-34	
29374185-8	2018	Furthermore, we demonstrated that TAK-165 inhibited autophagy in a HER2-independent manner.	TAK-165	34-41	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71	
30639343-9	2019	A selective ErbB2 tyrosine kinase inhibitor, mubritinib, impaired wound closure and decreased cyclin D1 expression in healthy HAECs, with less effect on cells from asthmatic patients, supporting diminished activity in asthmatic patients.	TAK-165	45-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	12-17	
30139932-9	2018	Exclusively inhibiting HER2/ErbB2 by Mubritinib did not affect the interaction of PTPIP51 with the MAPK signaling.	TAK-165	37-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-27	
30139932-9	2018	Exclusively inhibiting HER2/ErbB2 by Mubritinib did not affect the interaction of PTPIP51 with the MAPK signaling.	TAK-165	37-47	erb-b2 receptor tyrosine kinase 2	Homo sapiens	28-33	
27074819-4	2016	In this study, we showed that TAK165, a HER2 inhibitor, exhibited a strong synergy with ATRA to promote AML cell differentiation.	TAK-165	30-36	erb-b2 receptor tyrosine kinase 2	Homo sapiens	40-44	
15138566-3	2004	Both HER2/Neu inhibitor TAK165 and EGFR tyrosine kinase inhibitor gefitinib ("Iressa", ZD1839) successfully reduced the HER2/Neu-induced transactivation activity of the AR in PC-3 and DU-145 cells, suggesting that these inhibitors are possible therapeutic drugs for patients with hormone-refractory prostate cancer.	TAK-165	24-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9	
25407459-7	2016	Finally, we showed that the SNU-16R cell lines were sensitive to the human epidermal growth factor receptor 2 inhibitor mubritinib and the heat shock protein 90 inhibitor AUY922.	TAK-165	120-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	75-109	
26018524-11	2015	The ERBB2 inhibitor TAK-165 was synergistic with trametinib in KRAS-mutant cell lines.	TAK-165	20-27	erb-b2 receptor tyrosine kinase 2	Homo sapiens	4-9	
16771730-0	2006	Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.	TAK-165	48-55	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-10	
16771730-1	2006	PURPOSE: TAK-165 is a new potent inhibitor of human epidermal growth factor receptor 2 (HER2) tyrosine kinase.	TAK-165	9-16	erb-b2 receptor tyrosine kinase 2	Homo sapiens	52-86	
16771730-1	2006	PURPOSE: TAK-165 is a new potent inhibitor of human epidermal growth factor receptor 2 (HER2) tyrosine kinase.	TAK-165	9-16	erb-b2 receptor tyrosine kinase 2	Homo sapiens	88-92	
15138566-3	2004	Both HER2/Neu inhibitor TAK165 and EGFR tyrosine kinase inhibitor gefitinib ("Iressa", ZD1839) successfully reduced the HER2/Neu-induced transactivation activity of the AR in PC-3 and DU-145 cells, suggesting that these inhibitors are possible therapeutic drugs for patients with hormone-refractory prostate cancer.	TAK-165	24-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	10-13	
15138566-3	2004	Both HER2/Neu inhibitor TAK165 and EGFR tyrosine kinase inhibitor gefitinib ("Iressa", ZD1839) successfully reduced the HER2/Neu-induced transactivation activity of the AR in PC-3 and DU-145 cells, suggesting that these inhibitors are possible therapeutic drugs for patients with hormone-refractory prostate cancer.	TAK-165	24-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	120-124	
15138566-3	2004	Both HER2/Neu inhibitor TAK165 and EGFR tyrosine kinase inhibitor gefitinib ("Iressa", ZD1839) successfully reduced the HER2/Neu-induced transactivation activity of the AR in PC-3 and DU-145 cells, suggesting that these inhibitors are possible therapeutic drugs for patients with hormone-refractory prostate cancer.	TAK-165	24-30	erb-b2 receptor tyrosine kinase 2	Homo sapiens	125-128	
35452936-2	2022	Here, we retained (E)-4-methyl-2-(4-(trifluoromethyl)styryl)oxazole, a fragment of HER-2 inhibitor Mubritinib, and synthesized 32 novel compounds from it.	TAK-165	99-109	erb-b2 receptor tyrosine kinase 2	Homo sapiens	83-88